shortagewatch

Home / Companies / Glenmark

Company family · HQ IN

Glenmark: medicine shortages

GLENMARK · NSE

As of 2 Nov 2026, 105 Glenmark products have a reported shortage across 6 countries, covering 39 medicines.

Products short105rank #19 of 464
Medicines39active ingredients
Countries6/16
New in 90 days30+3 vs market pace
Typical duration6 monthsmedian so far
Manufacturing51%demand-driven 9%

Where

Canada4Germany24Italy3Spain28Czechia34Sweden12

Which therapeutic classes

Nervous system65Cardiovascular system13Cancer and immune system8Digestive tract and metabolism4Blood4Anti-infectives4Respiratory system3Dermatologicals2Various1Antiparasitics1

Why, compared with all companies

Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
GlenmarkGlenmark: Manufacturing problem 33 (31%)31%Glenmark: Increased demand 6 (6%)6%Glenmark: Commercial decision or withdrawal 24 (23%)23%Glenmark: Other 2 (2%)Glenmark: Not stated 40 (38%)38%All companiesAll companies: Manufacturing problem 4,893 (36%)36%All companies: Increased demand 1,873 (14%)14%All companies: Active ingredient shortage 367 (3%)All companies: Distribution or logistics 336 (2%)All companies: Commercial decision or withdrawal 435 (3%)All companies: Regulatory or licensing 131 (1%)All companies: Other 1,244 (9%)9%All companies: Not stated 4,221 (31%)31%

Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.

Latest changes

All changes

No changes recorded yet. Changes are tracked from our daily snapshots.

Open shortages over time

4243434431 Oct2026-10-31: 431 Nov2026-11-01: 432 Nov2026-11-02: 43

Products short per day in the 5 countries tracked since 31 Oct 2026, from our daily snapshots. The history lengthens every day.

When its current shortages began

05101520Dec: 0Jan ’25: 0Feb: 0FebMar: 0Apr: 0May: 0MayJun: 2Jul: 2Aug: 1AugSep: 0Oct: 1Nov: 2NovDec: 4Jan ’26: 1Feb: 5FebMar: 7Apr: 13May: 12MayJun: 3Jul: 4Aug: 8AugSep: 11Oct: 12Nov: 0Nov

Long-run trend in Canada

Canada dashboard
061218252017: 2220172018: 1120182023: 1120232024: 7720242025: 212120252026: 11112026

Canada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.

Against its peers

Viatris995Teva903Sandoz599Pfizer491Accord (Intas)484Stada349Zentiva340Fresenius Kabi339Apotex326Sun Pharma250Aurobindo226Towa (Pensa)201Krka187Sanofi158Glenmark105

Breadth vs depth

1101001,00010,0001101001,000Products short (log scale)Medicines affected (log scale)Viatris: 995 / 248ViatrisTeva: 903 / 289TevaSandoz: 599 / 198SandozPfizer: 491 / 122PfizerAccord (Intas): 484 / 151Accord (Intas)Stada: 349 / 140Zentiva: 340 / 159ZentivaFresenius Kabi: 339 / 81Apotex: 326 / 152Sun Pharma: 250 / 77Aurobindo: 226 / 111Towa (Pensa): 201 / 102Krka: 187 / 67Sanofi: 158 / 45Jamp: 151 / 74Baxter: 149 / 27Sawai: 148 / 68Hikma: 126 / 44Sanis: 98 / 54Cheplapharm: 86 / 28GSK: 85 / 38Advanz (Amdipharm): 81 / 24Nichi-Iko: 77 / 29Takeda: 76 / 10Johnson & Johnson: 75 / 19Neuraxpharm: 75 / 19Novartis: 70 / 32Bayer: 68 / 17Biomed: 64 / 21Daiichi Sankyo: 59 / 18Orifarm: 59 / 40Medochemie: 56 / 14Pharmascience: 51 / 32Marcan: 51 / 16Doc Generici: 50 / 25B. Braun: 49 / 17AA Pharma: 46 / 26H E: 46 / 15Octapharma: 42 / 6Jv E: 42 / 1Kyowa Pharmaceutical: 42 / 16Novo Nordisk: 41 / 8Odan: 41 / 31Aspen: 41 / 13Sterop: 41 / 16Nipro: 41 / 17Dr. Reddy's: 40 / 24Organon: 40 / 20Laboratoire Riva: 40 / 23Kern Pharma: 40 / 30Bausch Health: 39 / 30Bracco: 38 / 6G.L.: 38 / 13Tatsumi Kagaku: 38 / 24Otsuka: 37 / 4Eli Lilly: 37 / 12Piramal Critical: 35 / 13Imuna Pharm: 35 / 4AbbVie: 34 / 15Medical Valley: 34 / 8Orion: 34 / 24Rowex: 34 / 19Takata Pharmaceutical: 33 / 17Aristo: 32 / 16Norgine: 32 / 3Gedeon Richter: 31 / 11Eql: 31 / 9Guerbet: 30 / 5Lukas Heil-Betriebsst: 30 / 0Roche: 29 / 14Omega: 29 / 18Bgp: 29 / 18Holsten -: 29 / 3Menarini: 29 / 17Paladin: 28 / 17Grifols: 28 / 9Ge: 28 / 6Merck & Co. (MSD): 27 / 14Ferring: 27 / 7Glenmark: 105 / 39Glenmark

Further right: more products short. Higher: more different medicines affected.

Medicines short

Download CSV
MedicineWhere this company is shortProductsEarliest startMain reasonShort anywhere
Atomoxetine1131 Jan 2024Manufacturing problem11/16
Quetiapine1130 Sep 2024Manufacturing problem12/16
Olanzapine1015 Dec 2025Increased demand13/16
Galantamine92 Oct 2024Manufacturing problem7/16
Escitalopram413 Apr 2026Not stated10/16
Gabapentin44 May 2026Other9/16
Lacosamide429 May 2026Commercial decision or withdrawal6/16
Fingolimod33 Nov 2025Not stated9/16
Pregabalin310 Aug 2026Commercial decision or withdrawal11/16
Salmeterol and Fluticasone330 Apr 2026Commercial decision or withdrawal6/16
Telmisartan and Diuretics317 Mar 2026Not stated4/16
Varenicline313 Jul 2026Commercial decision or withdrawal4/16
Apremilast220 Sep 2026Not stated5/16
Clopidogrel223 Feb 2026Not stated9/16
Darunavir224 Apr 2026Not stated4/16
Mometasone216 Sep 2026Not stated3/16
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide216 Aug 2026Not stated3/16
Perindopril and Diuretics231 Mar 2026Not stated6/16
Rizatriptan215 Mar 2026Increased demand6/16
Rosuvastatin219 Aug 2026Not stated12/16
Simvastatin and Ezetimibe21 Mar 2026Commercial decision or withdrawal8/16
Ursodeoxycholic Acid25 Oct 2026Not stated7/16
Agomelatine19 Nov 2026Commercial decision or withdrawal1/16
Anastrozole114 May 2026Manufacturing problem5/16
Aprepitant15 May 2026Manufacturing problem12/16
Bendamustine115 Sep 2026Not stated7/16
Dabigatran Etexilate19 Oct 2026Not stated10/16
Deferasirox123 Apr 2026Not stated8/16
Dimethyl Fumarate123 Oct 2026Manufacturing problem5/16
Doxycycline131 Oct 2026Manufacturing problem7/16
Icatibant16 Oct 2026Not stated8/16
Ivermectin14 Oct 2026Not stated2/16
Linezolid126 Feb 2026Not stated7/16
Olmesartan Medoxomil129 Oct 2026Increased demand5/16
Olmesartan Medoxomil and Diuretics129 Oct 2026Increased demand4/16
Pramipexole11 Oct 2026Manufacturing problem6/16
Sitagliptin19 Nov 2026Commercial decision or withdrawal8/16
Topiramate11 Sep 2026Commercial decision or withdrawal8/16
Zonisamide114 Jun 2026Not stated4/16

Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.